News | November 09, 2008

NOPR Update: PET’s Impact Consistent Across Cancer Types, Imaging Indications

November 10, 2008 – Results from the National Oncologic PET Registry (NOPR) indicate that information provided by positron emission tomography (PET) was found to affect how clinicians manage their cancer patients’ care regardless of the cancer type and reason for ordering this imaging scan.

The results were published online Nov. 7 in the Journal of Nuclear Medicine.

Earlier this year, the study authors reported in the Journal of Clinical Oncology aggregate data contributed to the NOPR during year one of operation that demonstrated clinicians changed the intended care of more than one in three cancer patients as the result of PET scan findings.

After two years of operation, with nearly twice the data for analysis, the authors found the impact of PET to be very consistent for a wide range of cancers and indications.

Researchers analyzed data for 40,863 PET studies performed at 1,368 facilities participating in the NOPR nationwide during the registry’s first two years of operation. The impact of PET was assessed for 18 cancer types in patients with pathologically confirmed cancer and for indication for testing that included initial cancer staging (14,365 scans), restaging (14,584 scans) or detection of suspected cancer recurrence (11,914 scans).

“For the purposes of guiding clinical practice and shaping coverage policy, it is important to determine the relative effects of PET for different cancer types and indications for testing,” said Bruce Hillner, M.D., lead author for the study and professor and eminent university scholar in the Department of Internal Medicine at Virginia Commonwealth University. “These results strongly indicate the utility of PET for managing cancer patient care across a broad spectrum of cancer types and imaging indications.”

The NOPR was launched in May 2006 in response to the Center for Medicare and Medicaid Services’ (CMS) novel “Coverage with Evidence” policy to collect data through a clinical registry to inform the center’s FDG-PET coverage determination decisions for currently non-covered cancer indications. The project is sponsored by the Academy of Molecular Imaging (AMI) and managed by the American College of Radiology (ACR) and the ACR Imaging Network (ACRIN).

For more information: www.cancerPETregistry.org, http://jnm.snmjournals.org/cgi/content/abstract/jnumed.108.056713v1.

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...